OBJECTIVE: To study the time, intensity of symptoms, hormonal profile, and related morbidity of climacteric in women with untreated isolated growth hormone (GH) deficiency (IGHD). DESIGN: Women belonging to a large Brazilian kindred with IGHD due to a homozygous mutation in the GH-releasing hormone receptor gene were studied. None of them had ever received GH replacement therapy. A two-step protocol was performed. In the first case-control experiment, aimed to determine the age at climacteric, we compared eight women with IGHD and 32 normal women between 37 and 55 years of age. In the second cross-sectional experiment, aimed to determine the severity of climacteric symptoms, seven women with IGHD (aged 47-65 y) were compared with 13 controls (aged 44-65 y). The Kupperman Index scores, serum follicle-stimulating hormone, luteinizing hormone, prolactin, and estradiol levels were determined, and pelvic and mammary ultrasonography, mammography, and colpocytology were performed. RESULTS: The number of women with follicle-stimulating hormone above 20 mIU/mL was higher in women with IGHD than controls. Kupperman's Index was not different between the two groups. Menarche had been delayed and parity was lower in women with IGHD. Hormonal profile was similar, but prolactin was lower in women with IGHD. Uterine volume was smaller in women with IGHD, and endometrial thickness and ovarian volume were similar in the two groups. No difference in breast images or in colpocytology was observed between the two groups. CONCLUSIONS: Menarche was delayed and the beginning of climacteric is anticipated in untreated lifetime IGHD, but menopausal symptoms and hormonal profile resemble the normal climacteric.
OBJECTIVE: To study the time, intensity of symptoms, hormonal profile, and related morbidity of climacteric in women with untreated isolated growth hormone (GH) deficiency (IGHD). DESIGN:Women belonging to a large Brazilian kindred with IGHD due to a homozygous mutation in the GH-releasing hormone receptor gene were studied. None of them had ever received GH replacement therapy. A two-step protocol was performed. In the first case-control experiment, aimed to determine the age at climacteric, we compared eight women with IGHD and 32 normal women between 37 and 55 years of age. In the second cross-sectional experiment, aimed to determine the severity of climacteric symptoms, seven women with IGHD (aged 47-65 y) were compared with 13 controls (aged 44-65 y). The Kupperman Index scores, serum follicle-stimulating hormone, luteinizing hormone, prolactin, and estradiol levels were determined, and pelvic and mammary ultrasonography, mammography, and colpocytology were performed. RESULTS: The number of women with follicle-stimulating hormone above 20 mIU/mL was higher in women with IGHD than controls. Kupperman's Index was not different between the two groups. Menarche had been delayed and parity was lower in women with IGHD. Hormonal profile was similar, but prolactin was lower in women with IGHD. Uterine volume was smaller in women with IGHD, and endometrial thickness and ovarian volume were similar in the two groups. No difference in breast images or in colpocytology was observed between the two groups. CONCLUSIONS: Menarche was delayed and the beginning of climacteric is anticipated in untreated lifetime IGHD, but menopausal symptoms and hormonal profile resemble the normal climacteric.
Authors: R Salvatori; C Y Hayashida; M H Aguiar-Oliveira; J A Phillips; A H Souza; R G Gondo; S P Toledo; M M Conceicão; M Prince; H G Maheshwari; G Baumann; M A Levine Journal: J Clin Endocrinol Metab Date: 1999-03 Impact factor: 5.958
Authors: José Augusto Soares Barreto-Filho; Marta Regina S Alcântara; Roberto Salvatori; Martha Azevedo Barreto; Antônio Carlos Sobral Sousa; Valquíria Bastos; Anita Hermínia Souza; Rossana Maria C Pereira; Peter E Clayton; Matthew S Gill; Manuel Hermínio Aguiar-Oliveira Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Helio A Oliveira; Roberto Salvatori; Miriam P O Krauss; Carla R P Oliveira; Paula R C Silva; Manuel H Aguiar-Oliveira Journal: Eur J Endocrinol Date: 2003-04 Impact factor: 6.664
Authors: Carla R P Oliveira; Roberto Salvatori; Luciana M A Nóbrega; Erick O M Carvalho; Menilson Menezes; Catarine T Farias; Allan V O Britto; Rossana M C Pereira; Manuel H Aguiar-Oliveira Journal: Clin Endocrinol (Oxf) Date: 2008-07-01 Impact factor: 3.478
Authors: Manuel H Aguiar-Oliveira; Francielle T Oliveira; Rossana M C Pereira; Carla R P Oliveira; Amanda Blackford; Eugenia H O Valenca; Elenilde G Santos; Miburge B Gois-Junior; Rafael A Meneguz-Moreno; Vanessa P Araujo; Luis A Oliveira-Neto; Roque P Almeida; Mário A Santos; Natalia T Farias; Debora C R Silveira; Gabriel W Cabral; Flavia R Calazans; Juliane D Seabra; Tiago F Lopes; Endrigo O Rodrigues; Livia A Porto; Igor P Oliveira; Enaldo V Melo; Marco Martari; Roberto Salvatori Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958
Authors: Viviane C Campos; Mônica R Barrios; Roberto Salvatori; Roque Pacheco de Almeida; Enaldo V de Melo; Ana C S Nascimento; Amélia Ribeiro de Jesus; Manuel H Aguiar-Oliveira Journal: Endocrine Date: 2016-08-03 Impact factor: 3.633
Authors: Menilson Menezes; Roberto Salvatori; Luiza D Melo; Ívina E S Rocha; Carla R P Oliveira; Rossana M C Pereira; Anita H O Souza; Eugênia H O Valença; Enaldo V Melo; Viviane C Campos; Flavia O Costa; Manuel H Aguiar-Oliveira Journal: Endocrine Date: 2013-02-10 Impact factor: 3.633